alfuzosin vs mirabegron
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alfuzosin and mirabegron. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Uroxatral
Myrbetriq
Alfuzosin is a medicine that helps men with enlarged prostate glands. It relaxes the muscles in the prostate and bladder, making it easier to urinate.
Mirabegron is a medicine that helps control an overactive bladder. It relaxes the bladder muscle, allowing it to hold more urine.
This medicine treats the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate. BPH can cause problems with urination, such as difficulty starting or stopping, frequent urination, and feeling like you can't empty your bladder. Alfuzosin helps to improve these symptoms.
Mirabegron treats overactive bladder (OAB) in adults. OAB can cause you to feel a frequent and urgent need to urinate. It can also lead to accidental urine leakage (urge urinary incontinence).
Alfuzosin belongs to a class of drugs called alpha-1 blockers. It works by relaxing the muscles in the prostate and bladder neck. This relaxation allows urine to flow more freely, relieving the symptoms of BPH.
Mirabegron is a beta-3 adrenergic agonist. It works by relaxing the bladder muscle. This helps increase the bladder's capacity to store urine and reduces the urge to go.
- • Dizziness
- • Upper respiratory tract infection
- • Headache
- • Fatigue
- • High blood pressure
- • Common cold symptoms (nasopharyngitis)
- • Urinary tract infection
- • Headache
- Dyspnoea 89
- Drug Interaction 87
- Fatigue 87
- Acute Kidney Injury 79
- Dizziness 74
- Fatigue 2,215
- Headache 2,162
- Dizziness 2,093
- Fall 1,892
- Diarrhoea 1,861
Alfuzosin can cause your blood pressure to drop suddenly when you stand up, leading to dizziness or fainting. Be careful when standing up quickly, especially when you first start taking this medicine. If you have chest pain (angina), tell your doctor immediately. This medicine may also affect your heart rhythm. Tell your doctor if you have a history of heart problems.
Mirabegron can raise your blood pressure. Your doctor should check your blood pressure regularly, especially if you have high blood pressure. Mirabegron is not recommended if you have severe, uncontrolled high blood pressure (180/110 mm Hg or higher). Use caution if you have bladder outlet obstruction or are taking other medicines for overactive bladder, as it can increase the risk of urinary retention. Angioedema (swelling of the face, lips, tongue, or throat) has been reported.
This medicine is only for men and is not intended for use in women. It is not known if alfuzosin can harm an unborn baby or pass into breast milk.
It is not known if mirabegron can harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Also Compare, Nearby Drugs
Compare mirabegron with
How to Read This alfuzosin vs mirabegron Comparison
alfuzosin is classified in the Alpha-1 Blocker (BPH) drug class, while mirabegron sits within the Beta-3 Agonist (Overactive Bladder) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alfuzosin has 416 submissions while mirabegron has 10,223. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alfuzosin or mirabegron.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.